Trial for
Efficacy), evaluating INO-4800, its DNA vaccine candidate for COVID-19. Preliminary results show in a larger population that INO-4800 was generally safe, well-tolerated and immunogenic in all studied age groups.
Findings from the Phase 2 Clinical Trial:
The Phase 2 segment of the trial enrolled approximately 400 participants, 18 years of age or older, at 16 U.S. sites.
Participants received either INO-4800 (1.0 mg or 2.0 mg dose) or placebo at 0 and 4 weeks (randomized 3:3:1:1). Each dose was administered by intradermal injection followed by electroporation using INOVIO s CELLECTRA
®, its proprietary smart device.
Safety endpoints included systemic and local administration site reactions through 8 weeks post-dose one (or 4 weeks post-dose 2). Immunology endpoints included antigen-specific binding antibody titers, neutralization titers, and antigen-specific interferon-gamma (IFN-γ) cellular immune responses after two doses of the vaccine.
By carlyo on November 4, 2014.
The ‘Nifty Fifty (times 4)’, a program of Science Spark, presented by InfoComm International, are a group of 200 noted science and engineering professionals who will fan out across the Washington, D.C. area in the 2014-2015 school year to speak about their work and careers at various middle and high schools.
Meet Nifty Fifty Speaker Karen Elkins
Vaccines against diseases such as measles, polio, and whooping cough have greatly reduced deaths and suffering. These vaccines are designed to mimic the microbes that cause the disease. When given a vaccine, the body s immune system is inspired to ramp up and fight back against that microbe. As a result, immune defenders are ready and waiting when the real thing later starts an infection.
Share this article
Share this article
OXFORD, England, May 6, 2021 /PRNewswire/ Enesi Pharma ( Enesi ), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, is delighted to report positive top-line results from a new study evaluating the immune responses generated by an ImplaVax®-enabled unit solid-dose formulation of classical swine fever (CSF) vaccine.
The results showed that a novel solid-dose ImplaVax® formulation of a recombinant E2 antigen CSF virus vaccine delivered subcutaneously using the ImplaVax® needle-free injection device generated a stronger immune response than standard liquid CSF vaccine formulations, particularly in terms of CSF virus-specific T-cell responses.
Scientists at the Walter Reed Army Institute for Research demonstrated that biomarkers associated with traumatic brain injury were elevated among law enforcement and military personnel, particularly in active duty participants with longer duration of service.
Share this article
Share this article
OXFORD, England, May 5, 2021 /PRNewswire/ Enesi Pharma ( Enesi ), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it has achieved a key milestone in its project to develop needle-free thermostable unit solid-dose live vaccines with retained activity against Measles and Rubella. The project, which started in October 2019, received funding from the Bill & Melinda Gates Foundation.
The project established important proof-of-concept for ImplaVax®-enabled unit solid-dose presentations of both vaccines, demonstrating that each was thermally stable at temperatures of 40°C for three days and at 25°C for at least one month, and met key criteria for retained activity. Further longer-term stability studies are underway, and the Company is planning the immunogenicity studies needed to determine the next de